{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:02:48Z","timestamp":1789506168737,"version":"build-2803163510"},"reference-count":158,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:p>The androgen receptor (AR) is a key transcription factor in prostate cancer (PCa), whose enhanced and altered functions are known drivers of cancer progression. A key aspect of this is reprogramming of the AR cistrome, which consists of genome-wide enhancer-binding sites through which AR regulates gene expression. The magnitude and biological impact of the AR cistrome are impacted by the AR itself, including the responses to ligand, as well as the organization of the associated DNA response elements, and availability of pioneer factors, cofactors, and noncoding RNAs, all of which contribute to a functional transcription complex. In this review, we will examine, in the context of PCa progression, the factors that affect the binding of AR and its interacting partners at enhancers, with a focus on AR cistrome reprogramming. We also discuss the clinical utility of targeting the AR\u2013enhancer nucleoprotein complex and the potential of using the AR cistrome as a prognostic tool.<\/jats:p>","DOI":"10.1530\/erc-25-0529","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:31:49Z","timestamp":1780072309000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":1,"title":["Molecular determinants of AR\u2013enhancer interaction and cistrome reprogramming in prostate cancer progression"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8834-3221","authenticated-orcid":true,"given":"Rayzel C","family":"Fernandes","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle K","family":"Greenland","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3355-0928","authenticated-orcid":true,"given":"Moray J","family":"Campbell","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-0552","authenticated-orcid":true,"given":"Charlotte L","family":"Bevan","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026070909474756200_bib1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41586-020-2493-4","article-title":"Expanded encyclopaedias of DNA elements in the human and mouse genomes","volume":"583","author":"Moore","year":"2020","journal-title":"Nature"},{"key":"2026070909474756200_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0092-8674(81)90413-X","article-title":"Expression of a \u03b2-globin gene is enhanced by remote SV40 DNA sequences","volume":"27","author":"Banerji","year":"1981","journal-title":"Cell"},{"key":"2026070909474756200_bib3","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.tig.2021.02.002","article-title":"Transcriptional silencers: driving gene expression with the brakes on","volume":"37","author":"Segert","year":"2021","journal-title":"Trends Genet"},{"key":"2026070909474756200_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0092-8674(83)90015-6","article-title":"A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes","volume":"33","author":"Banerji","year":"1983","journal-title":"Cell"},{"key":"2026070909474756200_bib5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg3207","article-title":"Transcription factors: from enhancer binding to developmental control","volume":"13","author":"Spitz","year":"2012","journal-title":"Nat Rev Genet"},{"key":"2026070909474756200_bib6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"2026070909474756200_bib7","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1038\/emboj.2011.158","article-title":"The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis","volume":"30","author":"Massie","year":"2011","journal-title":"EMBO J"},{"key":"2026070909474756200_bib8","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1530\/ERC-19-0032","article-title":"Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers","volume":"26","author":"Stelloo","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2026070909474756200_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1042\/bse0400059","article-title":"DNA recognition by nuclear receptors","volume":"40","author":"Claessens","year":"2004","journal-title":"Essays Biochem"},{"key":"2026070909474756200_bib10","first-page":"2229","article-title":"A consensus DNA-binding site for the androgen receptor","volume":"6","author":"Roche","year":"1992","journal-title":"Mol Endocrinol"},{"key":"2026070909474756200_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/srep32611","article-title":"Refinement of the androgen response element based on ChIP-Seq in androgen-insensitive and androgen-responsive prostate cancer cell lines","volume":"6","author":"Wilson","year":"2016","journal-title":"Sci Rep"},{"key":"2026070909474756200_bib12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.embor.7401046","article-title":"New androgen receptor genomic targets show an interaction with the ETS1 transcription factor","volume":"8","author":"Massie","year":"2007","journal-title":"EMBO Rep"},{"key":"2026070909474756200_bib13","doi-asserted-by":"crossref","first-page":"8584","DOI":"10.1073\/pnas.1922159117","article-title":"Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG","volume":"117","author":"Wasmuth","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070909474756200_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature14248","article-title":"Integrative analysis of 111 reference human epigenomes","volume":"518","author":"Kundaje","year":"2015","journal-title":"Nature"},{"key":"2026070909474756200_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.tig.2023.10.007","article-title":"Pioneer factors: roles and their regulation in development","volume":"40","author":"Barral","year":"2024","journal-title":"Trends Genet"},{"key":"2026070909474756200_bib16","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1101\/gad.176826.111","article-title":"Pioneer transcription factors: establishing competence for gene expression","volume":"25","author":"Zaret","year":"2011","journal-title":"Genes Dev"},{"key":"2026070909474756200_bib17","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73358","article-title":"A test of the pioneer factor hypothesis using ectopic liver gene activation","volume":"11","author":"Hansen","year":"2022","journal-title":"Elife"},{"key":"2026070909474756200_bib18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","article-title":"Prostate cancer reactivates developmental epigenomic programs during metastatic progression","volume":"52","author":"Pomerantz","year":"2020","journal-title":"Nat Genet"},{"key":"2026070909474756200_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/edrv.23.2.0460","article-title":"Androgen receptor (AR) coregulators: an overview","volume":"23","author":"Heinlein","year":"2002","journal-title":"Endocr Rev"},{"key":"2026070909474756200_bib20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cell.2013.07.011","article-title":"Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes","volume":"154","author":"Narlikar","year":"2013","journal-title":"Cell"},{"key":"2026070909474756200_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res"},{"key":"2026070909474756200_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat Rev Genet"},{"key":"2026070909474756200_bib23","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"2026070909474756200_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.tibs.2022.03.002","article-title":"Beyond the marks: reader-effectors as drivers of epigenetics and chromatin engineering","volume":"47","author":"Franklin","year":"2022","journal-title":"Trends Biochem Sci"},{"key":"2026070909474756200_bib25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13059-021-02322-1","article-title":"Mechanisms of enhancer action: the known and the unknown","volume":"22","author":"Panigrahi","year":"2021","journal-title":"Genome Biol"},{"key":"2026070909474756200_bib26","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1073\/pnas.1324151111","article-title":"Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation","volume":"111","author":"Hsieh","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070909474756200_bib27","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nature12451","article-title":"lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs","volume":"500","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"2026070909474756200_bib28","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1039\/B803580F","article-title":"Long-range chromosomal interactions and gene regulation","volume":"4","author":"Miele","year":"2008","journal-title":"Mol Biosyst"},{"key":"2026070909474756200_bib29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026070909474756200_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1101\/gr.230243.117","article-title":"An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells","volume":"29","author":"Zhang","year":"2019","journal-title":"Genome Res"},{"key":"2026070909474756200_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","article-title":"Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"2026070909474756200_bib32","article-title":"EAU PCa guidelines","author":"Panel PCPG","year":"2025"},{"key":"2026070909474756200_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"2026070909474756200_bib34","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"2026070909474756200_bib35","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"2026070909474756200_bib36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"2026070909474756200_bib37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3390\/cancers13030509","article-title":"Eighty years of targeting androgen receptor activity in prostate cancer: the fight goes on","volume":"13","author":"Estebanez-Perpina","year":"2021","journal-title":"Cancers"},{"key":"2026070909474756200_bib38","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"2026070909474756200_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070909474756200_bib40","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"2026070909474756200_bib41","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"key":"2026070909474756200_bib42","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2026070909474756200_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.mce.2011.12.019","article-title":"Androgen receptor (AR) aberrations in castration-resistant prostate cancer","volume":"360","author":"Waltering","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2026070909474756200_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41416-018-0172-0","article-title":"Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases","volume":"119","author":"Kallio","year":"2018","journal-title":"Br J Cancer"},{"key":"2026070909474756200_bib45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J Clin Invest"},{"key":"2026070909474756200_bib46","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccell.2019.03.001","article-title":"CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis","volume":"35","author":"Augello","year":"2019","journal-title":"Cancer Cell"},{"key":"2026070909474756200_bib47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","article-title":"FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes","volume":"571","author":"Adams","year":"2019","journal-title":"Nature"},{"key":"2026070909474756200_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41588-024-01893-6","article-title":"NSD2 is a requisite subunit of the AR\/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis","volume":"56","author":"Parolia","year":"2024","journal-title":"Nat Genet"},{"key":"2026070909474756200_bib49","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1541-7786.MCR-18-0087","article-title":"Novel lncRNA LINC00844 regulates prostate cancer cell migration and invasion through AR signaling","volume":"16","author":"Lingadahalli","year":"2018","journal-title":"Mol Cancer Res"},{"key":"2026070909474756200_bib50","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/onc.2016.334","article-title":"Cell cycle-coupled expansion of AR activity promotes cancer progression","volume":"36","author":"McNair","year":"2017","journal-title":"Oncogene"},{"key":"2026070909474756200_bib51","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat Genet"},{"key":"2026070909474756200_bib52","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.039297","article-title":"Genome-wide analysis of androgen receptor binding and transcriptomic analysis in mesenchymal subsets during prostate development","volume":"12","author":"Nash","year":"2019","journal-title":"Dis Model Mech"},{"key":"2026070909474756200_bib53","first-page":"18","article-title":"Androgen receptor (AR) cistrome in prostate differentiation and cancer progression","volume":"5","author":"Wang","year":"2017","journal-title":"Am J Clin Exp Urol"},{"key":"2026070909474756200_bib54","doi-asserted-by":"crossref","first-page":"502","DOI":"10.15252\/embj.201490306","article-title":"Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer","volume":"34","author":"Chen","year":"2015","journal-title":"EMBO J"},{"key":"2026070909474756200_bib55","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1002\/1878-0261.12572","article-title":"Factors that influence the androgen receptor cistrome in benign and malignant prostate cells","volume":"13","author":"Copeland","year":"2019","journal-title":"Mol Oncol"},{"key":"2026070909474756200_bib56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccr.2012.11.010","article-title":"The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man","volume":"23","author":"Sharma","year":"2013","journal-title":"Cancer Cell"},{"key":"2026070909474756200_bib57","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.15252\/emmm.201505424","article-title":"Androgen receptor profiling predicts prostate cancer outcome","volume":"7","author":"Stelloo","year":"2015","journal-title":"EMBO Mol Med"},{"key":"2026070909474756200_bib58","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","article-title":"An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer","volume":"23","author":"Davies","year":"2021","journal-title":"Nat Cell Biol"},{"key":"2026070909474756200_bib59","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","article-title":"Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing","volume":"174","author":"Viswanathan","year":"2018","journal-title":"Cell"},{"key":"2026070909474756200_bib60","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","article-title":"A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer","volume":"174","author":"Takeda","year":"2018","journal-title":"Cell"},{"key":"2026070909474756200_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115312","article-title":"CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer","volume":"44","author":"Xiang","year":"2025","journal-title":"Cell Rep"},{"key":"2026070909474756200_bib62","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-020-14644-y","article-title":"Androgen receptor-binding sites are highly mutated in prostate cancer","volume":"11","author":"Morova","year":"2020","journal-title":"Nat Commun"},{"key":"2026070909474756200_bib63","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccell.2019.10.005","article-title":"Cistrome partitioning reveals convergence of somatic mutations and risk variants on master transcription regulators in primary prostate tumors","volume":"36","author":"Mazrooei","year":"2019","journal-title":"Cancer Cell"},{"key":"2026070909474756200_bib64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13059-021-02339-6","article-title":"Functional mapping of androgen receptor enhancer activity","volume":"22","author":"Huang","year":"2021","journal-title":"Genome Biol"},{"key":"2026070909474756200_bib65","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1101\/gr.135665.111","article-title":"Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus","volume":"22","author":"Zhang","year":"2012","journal-title":"Genome Res"},{"key":"2026070909474756200_bib66","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1158\/0008-5472.CAN-14-1030","article-title":"CtBP2 modulates the androgen receptor to promote prostate cancer progression","volume":"74","author":"Takayama","year":"2014","journal-title":"Cancer Res"},{"key":"2026070909474756200_bib67","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/humu.22909","article-title":"Putative prostate cancer risk SNP in an androgen receptor-binding site of the melanophilin gene illustrates enrichment of risk SNPs in androgen receptor target sites","volume":"37","author":"Bu","year":"2016","journal-title":"Hum Mutat"},{"key":"2026070909474756200_bib68","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1210\/me.2013-1098","article-title":"Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element","volume":"27","author":"Clinckemalie","year":"2013","journal-title":"Mol Endocrinol"},{"key":"2026070909474756200_bib69","doi-asserted-by":"crossref","first-page":"T87","DOI":"10.1530\/ERC-13-0470","article-title":"Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer","volume":"21","author":"Ware","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2026070909474756200_bib70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat Med"},{"key":"2026070909474756200_bib71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Hu","year":"2009","journal-title":"Cancer Res"},{"key":"2026070909474756200_bib72","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1158\/0008-5472.CAN-09-0919","article-title":"Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens","volume":"69","author":"Waltering","year":"2009","journal-title":"Cancer Res"},{"key":"2026070909474756200_bib73","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/onc.2011.401","article-title":"Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer","volume":"31","author":"Urbanucci","year":"2012","journal-title":"Oncogene"},{"key":"2026070909474756200_bib74","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/s41588-024-01826-3","article-title":"Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer","volume":"56","author":"Zhao","year":"2024","journal-title":"Nat Genet"},{"key":"2026070909474756200_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad045","article-title":"Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer","volume":"5","author":"Zivanovic","year":"2023","journal-title":"NAR Cancer"},{"key":"2026070909474756200_bib76","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.annonc.2025.10.1236","article-title":"Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer","volume":"37","author":"Virtanen","year":"2025","journal-title":"Ann Oncol"},{"key":"2026070909474756200_bib77","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ajur.2020.01.001","article-title":"Regulation of androgen receptor variants in prostate cancer","volume":"7","author":"Zhu","year":"2020","journal-title":"Asian J Urol"},{"key":"2026070909474756200_bib78","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/pcan.2016.17","article-title":"Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting","volume":"19","author":"Antonarakis","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026070909474756200_bib79","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.euf.2025.03.017","article-title":"Reprogramming of androgen receptor activity in castration-resistant prostate cancer is shaped by truncated variants","volume":"11","author":"Lawrence","year":"2025","journal-title":"Eur Urol Focus"},{"key":"2026070909474756200_bib80","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1073\/pnas.1718811115","article-title":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","volume":"115","author":"Chen","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070909474756200_bib81","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J Clin Investig"},{"key":"2026070909474756200_bib82","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molcel.2018.08.029","article-title":"ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer","volume":"72","author":"Cai","year":"2018","journal-title":"Mol Cel"},{"key":"2026070909474756200_bib83","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","article-title":"ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer","volume":"35","author":"Cato","year":"2019","journal-title":"Cancer Cell"},{"key":"2026070909474756200_bib84","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/nar\/gkx1306","article-title":"Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer","volume":"46","author":"He","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2026070909474756200_bib85","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.juro.2014.08.043","article-title":"The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells","volume":"193","author":"Lu","year":"2015","journal-title":"J Urol"},{"key":"2026070909474756200_bib86","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1038\/s41598-022-09371-x","article-title":"Cistrome and transcriptome analysis identifies unique androgen receptor (AR) and AR-V7 splice variant chromatin binding and transcriptional activities","volume":"12","author":"Basil","year":"2022","journal-title":"Sci Rep"},{"key":"2026070909474756200_bib87","doi-asserted-by":"crossref","first-page":"29782","DOI":"10.18632\/oncotarget.4927","article-title":"FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer","volume":"6","author":"Jones","year":"2015","journal-title":"Oncotarget"},{"key":"2026070909474756200_bib88","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"2026070909474756200_bib89","doi-asserted-by":"crossref","first-page":"10929","DOI":"10.1093\/nar\/gkac861","article-title":"A cryptic transactivation domain of EZH2 binds AR and AR\u2019s splice variant, promoting oncogene activation and tumorous transformation","volume":"50","author":"Wang","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2026070909474756200_bib90","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.cell.2008.01.018","article-title":"FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription","volume":"132","author":"Lupien","year":"2008","journal-title":"Cell"},{"key":"2026070909474756200_bib91","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1242\/dev.01917","article-title":"Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation","volume":"132","author":"Gao","year":"2005","journal-title":"Development"},{"key":"2026070909474756200_bib92","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/emboj.2011.328","article-title":"Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer","volume":"30","author":"Sahu","year":"2011","journal-title":"EMBO J"},{"key":"2026070909474756200_bib93","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nature10006","article-title":"Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA","volume":"474","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"2026070909474756200_bib94","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1038\/ncomms4972","article-title":"Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program","volume":"5","author":"Jin","year":"2014","journal-title":"Nat Commun"},{"key":"2026070909474756200_bib95","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41422-019-0203-2","article-title":"Forkhead domain mutations in FOXA1 drive prostate cancer progression","volume":"29","author":"Gao","year":"2019","journal-title":"Cell Res"},{"key":"2026070909474756200_bib96","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41422-019-0204-1","article-title":"Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression","volume":"29","author":"Xu","year":"2019","journal-title":"Cell Res"},{"key":"2026070909474756200_bib97","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41586-019-1347-4","article-title":"Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer","volume":"571","author":"Parolia","year":"2019","journal-title":"Nature"},{"key":"2026070909474756200_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/science.adv2367","article-title":"Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity","volume":"389","author":"Eyunni","year":"2025","journal-title":"Science"},{"key":"2026070909474756200_bib99","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.molcel.2009.10.020","article-title":"The homeodomain protein HOXB13 regulates the cellular response to androgens","volume":"36","author":"Norris","year":"2009","journal-title":"Mol Cel"},{"key":"2026070909474756200_bib100","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2500327122","article-title":"Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer","volume":"122","author":"Ersoy-Fazlioglu","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070909474756200_bib101","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1476-4598-9-124","article-title":"HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling","volume":"9","author":"Kim","year":"2010","journal-title":"Mol Cancer"},{"key":"2026070909474756200_bib102","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1093\/nar\/gkt1382","article-title":"Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer","volume":"42","author":"Wu","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2026070909474756200_bib103","doi-asserted-by":"crossref","first-page":"18261","DOI":"10.1073\/pnas.1421415111","article-title":"GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex","volume":"111","author":"He","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070909474756200_bib104","doi-asserted-by":"crossref","first-page":"0008","DOI":"10.47248\/chp2502020008","article-title":"A hierarchy of luminal transcription factors defines AR cistrome and is lost in neuroendocrine prostate cancer","volume":"2","author":"Keo","year":"2025","journal-title":"Cancer Heterog Plast"},{"key":"2026070909474756200_bib105","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.euo.2023.09.012","article-title":"Clinical and functional analyses of an African-ancestry gain-of-function HOXB13 variant implicated in aggressive prostate cancer","volume":"7","author":"Kanayama","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026070909474756200_bib106","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"key":"2026070909474756200_bib107","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1158\/1541-7786.MCR-18-1231","article-title":"The pioneering role of GATA2 in androgen receptor variant regulation is controlled by bromodomain and extraterminal proteins in castrate-resistant prostate cancer","volume":"17","author":"Chaytor","year":"2019","journal-title":"Mol Cancer Res"},{"key":"2026070909474756200_bib108","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1038\/s41388-021-01887-2","article-title":"Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells","volume":"40","author":"Launonen","year":"2021","journal-title":"Oncogene"},{"key":"2026070909474756200_bib109","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"key":"2026070909474756200_bib110","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"2026070909474756200_bib111","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1038\/s41388-021-01982-4","article-title":"Going beyond polycomb: EZH2 functions in prostate cancer","volume":"40","author":"Park","year":"2021","journal-title":"Oncogene"},{"key":"2026070909474756200_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1021845","article-title":"Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2","volume":"12","author":"Labaf","year":"2022","journal-title":"Front Oncol"},{"key":"2026070909474756200_bib113","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1038\/s41467-018-07511-4","article-title":"NSD2 is a conserved driver of metastatic prostate cancer progression","volume":"9","author":"Aytes","year":"2018","journal-title":"Nat Commun"},{"key":"2026070909474756200_bib114","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1158\/1055-9965.EPI-10-0555","article-title":"Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development","volume":"19","author":"Bianco-Miotto","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026070909474756200_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110417","article-title":"A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer","volume":"38","author":"Tang","year":"2022","journal-title":"Cell Rep"},{"key":"2026070909474756200_bib116","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov"},{"key":"2026070909474756200_bib117","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.1158\/0008-5472.CAN-06-1023","article-title":"Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer","volume":"66","author":"Agoulnik","year":"2006","journal-title":"Cancer Res"},{"key":"2026070909474756200_bib118","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/sj.onc.1206342","article-title":"Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development","volume":"22","author":"Halkidou","year":"2003","journal-title":"Oncogene"},{"key":"2026070909474756200_bib119","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1097-2765(02)00471-9","article-title":"Formation of the androgen receptor transcription complex","volume":"9","author":"Shang","year":"2002","journal-title":"Mol Cel"},{"key":"2026070909474756200_bib120","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1158\/0008-5472.CAN-17-0314","article-title":"Therapeutic targeting of the CBP\/p300 bromodomain blocks the growth of castration-resistant prostate cancer","volume":"77","author":"Jin","year":"2017","journal-title":"Cancer Res"},{"key":"2026070909474756200_bib121","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41588-025-02336-6","article-title":"Targeting histone H2B acetylated enhanceosomes via p300\/CBP degradation in prostate cancer","volume":"57","author":"Luo","year":"2025","journal-title":"Nat Genet"},{"key":"2026070909474756200_bib122","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccell.2016.04.012","article-title":"TRIM24 is an oncogenic transcriptional activator in prostate cancer","volume":"29","author":"Groner","year":"2016","journal-title":"Cancer Cell"},{"key":"2026070909474756200_bib123","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.canlet.2022.01.009","article-title":"ETS factors in prostate cancer","volume":"530","author":"Qian","year":"2022","journal-title":"Cancer Lett"},{"key":"2026070909474756200_bib124","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-3-030-32656-2_18","volume-title":"Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and Progression","author":"Nicholas","year":"2019"},{"key":"2026070909474756200_bib125","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"2026070909474756200_bib126","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nm.3216","article-title":"ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss","volume":"19","author":"Chen","year":"2013","journal-title":"Nat Med"},{"key":"2026070909474756200_bib127","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1158\/2159-8290.CD-19-0189","article-title":"CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation","volume":"9","author":"Rasool","year":"2019","journal-title":"Cancer Discov"},{"key":"2026070909474756200_bib128","doi-asserted-by":"crossref","first-page":"e1000384","DOI":"10.1371\/journal.pbio.1000384","article-title":"A large fraction of extragenic RNA Pol II transcription sites overlap enhancers","volume":"8","author":"De Santa","year":"2010","journal-title":"PLoS Biol"},{"key":"2026070909474756200_bib129","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature09033","article-title":"Widespread transcription at neuronal activity-regulated enhancers.","volume":"465","author":"Kim","year":"2010","journal-title":"Nature"},{"key":"2026070909474756200_bib130","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nsmb.2085","article-title":"Transcription initiation platforms and GTF recruitment at tissue-specific enhancers and promoters","volume":"18","author":"Koch","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"2026070909474756200_bib131","doi-asserted-by":"crossref","DOI":"10.1038\/srep33510","article-title":"Global analysis of transcription in castration-resistant prostate cancer cells uncovers active enhancers and direct androgen receptor targets","volume":"6","author":"Toropainen","year":"2016","journal-title":"Sci Rep"},{"key":"2026070909474756200_bib132","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.celrep.2016.03.038","article-title":"Activation of P-TEFb by androgen receptor-regulated enhancer RNAs in castration-resistant prostate cancer","volume":"15","author":"Zhao","year":"2016","journal-title":"Cell Rep"},{"key":"2026070909474756200_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2016.03.022","article-title":"Revisiting lncRNAs: how do you know yours is not an eRNA?","volume":"62","author":"Espinosa","year":"2016","journal-title":"Mol Cel"},{"key":"2026070909474756200_bib134","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13202","article-title":"Enhancer RNA: what we know and what we can achieve","volume":"55","author":"Han","year":"2022","journal-title":"Cell Prolif"},{"key":"2026070909474756200_bib135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0092-8674(00)80711-4","article-title":"A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex","volume":"97","author":"Lanz","year":"1999","journal-title":"Cell"},{"key":"2026070909474756200_bib136","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.18632\/oncotarget.1846","article-title":"The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer","volume":"5","author":"Prensner","year":"2014","journal-title":"Oncotarget"},{"key":"2026070909474756200_bib137","doi-asserted-by":"crossref","first-page":"17861","DOI":"10.1074\/jbc.M116.718536","article-title":"Androgen-induced long noncoding RNA (lncRNA) SOCS2-AS1 promotes cell growth and inhibits apoptosis in prostate cancer cells","volume":"291","author":"Misawa","year":"2016","journal-title":"J Biol Chem"},{"key":"2026070909474756200_bib138","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.celrep.2015.08.069","article-title":"LncRNA HOTAIR enhances the androgen-receptor-mediated transcriptional program and drives castration-resistant prostate cancer","volume":"13","author":"Zhang","year":"2015","journal-title":"Cell Rep"},{"key":"2026070909474756200_bib139","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41419-020-02856-5","article-title":"LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression","volume":"11","author":"Yao","year":"2020","journal-title":"Cell Death Dis"},{"key":"2026070909474756200_bib140","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.tem.2011.07.006","article-title":"Androgen receptor-driven chromatin looping in prostate cancer","volume":"22","author":"Wu","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"2026070909474756200_bib141","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.molcel.2005.07.018","article-title":"Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking","volume":"19","author":"Wang","year":"2005","journal-title":"Mol Cel"},{"key":"2026070909474756200_bib142","doi-asserted-by":"crossref","first-page":"8526","DOI":"10.1093\/nar\/gkt644","article-title":"CCAR1 promotes chromatin loading of androgen receptor (AR) transcription complex by stabilizing the association between AR and GATA2","volume":"41","author":"Seo","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2026070909474756200_bib143","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/emboj.2011.154","article-title":"Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth","volume":"30","author":"Chen","year":"2011","journal-title":"EMBO J"},{"key":"2026070909474756200_bib144","article-title":"Androgen receptor acts as the transcriptional repressor of the nuclear receptor LRH-1 via the androgen-driven chromatin looping conformation in prostate cancer","volume":"13","author":"You","year":"2025","journal-title":"Genes Dis"},{"key":"2026070909474756200_bib145","doi-asserted-by":"crossref","first-page":"9494","DOI":"10.1038\/s41467-024-53758-5","article-title":"Decoding the epigenetics and chromatin loop dynamics of androgen receptor-mediated transcription","volume":"15","author":"Alt\u0131nta\u015f","year":"2024","journal-title":"Nat Commun"},{"key":"2026070909474756200_bib146","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13148-022-01278-8","article-title":"Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer","volume":"14","author":"Severson","year":"2022","journal-title":"Clin Epigenet"},{"key":"2026070909474756200_bib147","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1038\/s41467-022-35135-2","article-title":"Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential","volume":"13","author":"Kneppers","year":"2022","journal-title":"Nat Commun"},{"key":"2026070909474756200_bib148","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"key":"2026070909474756200_bib149","first-page":"705","article-title":"Profiling of androgen-dependent enhancer RNAs expression in human prostate tumors: search for malignancy transition markers","volume":"13","author":"Nishimura","year":"2021","journal-title":"Res Rep Urol"},{"key":"2026070909474756200_bib150","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/pros.24356","article-title":"Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer","volume":"82","author":"Kwan","year":"2022","journal-title":"Prostate"},{"key":"2026070909474756200_bib151","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ajur.2016.09.003","article-title":"Non-invasive actionable biomarkers for metastatic prostate cancer","volume":"3","author":"Luo","year":"2016","journal-title":"Asian J Urol"},{"key":"2026070909474756200_bib152","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first-and second-line abiraterone and enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026070909474756200_bib153","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026070909474756200_bib154","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54847-1","article-title":"AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients","volume":"15","author":"Knutson","year":"2024","journal-title":"Nat Commun"},{"key":"2026070909474756200_bib155","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/1878-0261.12933","article-title":"Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment","volume":"15","author":"Boerrigter","year":"2021","journal-title":"Mol Oncol"},{"key":"2026070909474756200_bib156","doi-asserted-by":"crossref","first-page":"38551","DOI":"10.18632\/oncotarget.9535","article-title":"Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"key":"2026070909474756200_bib157","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.18632\/oncotarget.2691","article-title":"Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer","volume":"5","author":"Wang","year":"2014","journal-title":"Oncotarget"},{"key":"2026070909474756200_bib158","article-title":"Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Cui","year":"2016","journal-title":"Sci Rep"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/6\/ERC-25-0529.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/6\/ERC-25-0529.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0529\/520058\/erc-25-0529.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0529\/520058\/erc-25-0529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:48:13Z","timestamp":1783604893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/6\/e250529\/77598\/Molecular-determinants-of-AR-enhancer-interaction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":158,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0529","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"e250529"}}